Anxiety and Panic Disorders Drugs Market - Trends and Forecasts by Technavio

Technavio has published a new report on the global anxiety and panic disorders drugs market from 2017-2021. (Graphic: Business Wire)

???pagination.previous??? ???pagination.next???

LONDON--()--Technavio’s latest report on the global anxiety and panic disorders drugs market provides an analysis on the most important trends expected to impact the market outlook from 2017-2021. Technavio defines an emerging trend as a factor that has the potential to significantly impact the market and contribute to its growth or decline.

Sapna Jha, a lead analyst from Technavio, specializing in research on the central nervous system sector, says, “Prozac represented the pharmaceutical market in the 1990s with its multi-billion-dollar drug sales, which made depression more curable. Then followed the other blockbuster drugs such as XANAX, which became the first drug to receive the US FDA's approval for the treatment of anxiety and panic attacks.”

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.

The top three emerging trends driving the global anxiety and panic disorders drugs market according to Technavio research analysts are:

Synergistic effects of medication aided with neuromodulation devices

The global anxiety and panic disorders drugs market has witnessed many repurposed and off-label drugs for their treatment. The traditional therapeutic approach has left people only with a partial treatment, resulting in a large pool of untreated or partially treated population. Therefore, to offset the impact of these drugs, many novel techniques have been developed over the past few years to satisfy the demand for novel treatment approach for these disorders.

Non-invasive procedure along with other medications has completely removed the use of sedatives or anesthesia and alleviated seizures or loss of consciousness. Such benefits have led to its high acceptance in the developed countries,” according to Sapna.

Growing public awareness

The growing public awareness about depression is expected to increase the acceptability of various drugs. The Anxiety and Depression Association of America, Mental Health America, Depression and Bipolar Support Alliance, Suicide Awareness, Voices of Education, and Freedom from Fear are some of the non-profit organizations that are involved in spreading awareness about depression and its implications.

These organizations mostly rely on social media and word-of-mouth techniques to communicate with their target audience. They use blogs, Facebook posts, tweets, and YouTube videos extensively to increase awareness.

Evolving scientists’ interest for development of novel therapeutics

The scientists have been targeting a variety of innovative pathways for the treatment of anxiety and panic disorders including the traditional approaches such as dopaminergic and serotonergic pathways. However, the continuous focus of scientists to develop novel therapeutics have led to the discovery of some new targets that may serve helpful for the treatment of anxiety and panic disorders.

The key vendors are as follows:

  • AstraZeneca
  • Eli Lilly
  • GlaxoSmithKline
  • Pfizer

Browse Related Reports:

Become a Technavio Insights member and access all three of these reports for a fraction of their original cost. As a Technavio Insights member, you will have immediate access to new reports as they’re published in addition to all 6,000+ existing reports covering segments like in-vitro diagnostics, oncology, and vaccines. This subscription nets you thousands in savings, while staying connected to Technavio’s constant transforming research library, helping you make informed business decisions more efficiently.

About Technavio

Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.

Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users.

If you are interested in more information, please contact our media team at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com

Release Summary

Technavio’s latest report on the global anxiety and panic disorders drugs market provides an analysis of the most important trends expected to impact the market outlook from 2017-2021.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com